Septerna ($SEPN) Insider Trading & Smart Money Activity
Septerna, Inc. ($SEPN) has 8 insider trades, 2 13F position changes and 3 analyst ratings on file. Insiders filed 8 Form 4 transactions in the last 12 months, none of them open-market purchases or sales.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 0
- Net insider $ (12 mo)
- $0
- Congress trades (12 mo)
- 0
- 13F moves on file
- 2
- Analyst ratings on file
- 3
SEPN insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 0 / 2 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All SEPN insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Analyst | Truist Securities | Reiterates to buy | PT $43 | +5.2% | -0.5% | Read | |||||
| Analyst | HC Wainwright | Reiterates to buy | PT $40 | +5.2% | -0.5% | Read | |||||
| Analyst | Guggenheim | Reiterates to buy | PT $45 | +5.2% | -0.5% | Read | |||||
| Insider | Samira ShaikhlyChief People Officer | Sell (Option exercise) | 2.18K sh | -3.7% | -3.3% | — | |||||
| Insider | Samira ShaikhlyChief People Officer | Buy (Option exercise) | 2.18K sh | $14.83K | -3.7% | -3.3% | — | ||||
| Insider | Shalini Sharp | Buy (Grant or award) | 15K sh | -10.4% | -10.3% | Read | |||||
| Insider | L.P. Ra Capital Management | Buy (Grant or award) | 15K sh | -10.4% | -10.3% | Read | |||||
| Insider | Alan Ezekowitz | Buy (Grant or award) | 15K sh | -10.4% | -10.3% | Read | |||||
| Insider | Bernard Coulie | Buy (Grant or award) | 15K sh | -10.4% | -10.3% | Read | |||||
| Insider | Daniel LongSVP, Drug Discovery | Sell (Option exercise) | 15K sh | -0.3% | -1.9% | — | |||||
| Insider | Daniel LongSVP, Drug Discovery | Buy (Option exercise) | 15K sh | $81.37K | -0.3% | -1.9% | — | ||||
| 13F | Driehaus Capital Management | Reduced | -413.90K sh | $147.21M | +5.2% | +33.7% | Read | ||||
| 13F | Driehaus Capital Management | Reduced | -413.90K sh | $150.06M | +5.2% | +33.7% | Read |
1W / 1M / 6M = how SEPN moved from the trade or filing date.
Insider trading in SEPN: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Samira Shaikhly | Chief People Officer | 2 | — | Jun 29, 2026 | |
| Shalini Sharp | 1 | — | Jun 26, 2026 | ||
| L.P. Ra Capital Management | 1 | — | Jun 26, 2026 | ||
| Alan Ezekowitz | 1 | — | Jun 26, 2026 | ||
| Bernard Coulie | 1 | — | Jun 26, 2026 | ||
| Daniel Long | SVP, Drug Discovery | 2 | — | Jun 22, 2026 |
Institutions moving SEPN (13F)
Analyst ratings on SEPN
Frequently asked questions
What is the latest insider trade in SEPN?
Samira Shaikhly, Chief People Officer filed a sell (option exercise) of 2.18K sh on Jun 29, 2026.
Which institutions changed their SEPN positions?
Recent 13F filers moving the stock include Driehaus Capital Management.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.